Truist Financial Corp Invests $48,000 in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Truist Financial Corp bought a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCYGet Rating) during the first quarter, according to its most recent filing with the SEC. The fund bought 37,462 shares of the company’s stock, valued at approximately $48,000. Truist Financial Corp owned 0.25% of Unicycive Therapeutics at the end of the most recent reporting period.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on Unicycive Therapeutics in a research note on Wednesday, June 8th. They set a “buy” rating and a $9.00 target price on the stock.

Unicycive Therapeutics Stock Performance

Shares of Unicycive Therapeutics stock opened at $0.74 on Monday. Unicycive Therapeutics, Inc. has a 52-week low of $0.62 and a 52-week high of $3.38. The stock’s 50-day simple moving average is $0.88 and its 200 day simple moving average is $1.11. The stock has a market capitalization of $11.12 million and a P/E ratio of -0.81.

Unicycive Therapeutics (NASDAQ:UNCYGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Equities research analysts forecast that Unicycive Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.

Unicycive Therapeutics Profile

(Get Rating)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with's FREE daily email newsletter.